血浆成纤维细胞生长因子 21 水平与全国多中心队列研究中肌肉量和肌肉力量的关系：韩国虚弱和衰老队列研究。

Association of plasma FGF21 levels with muscle mass and muscle strength in a national multicentre cohort study: Korean Frailty and Aging Cohort Study.

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.

Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea.

出版信息

Age Ageing. 2021 Nov 10;50(6):1971-1978. doi: 10.1093/ageing/afab178.

DOI:10.1093/ageing/afab178

PMID:34591968

Abstract

BACKGROUND

despite of the beneficial effects of fibroblast growth factor (FGF) 21 in several metabolic diseases, the association of plasma FGF21 with muscle mass and muscle strength is still unclear.

METHODS

a total of 386 community-dwelling older adults aged 70-84 years were analysed. Appendicular skeletal muscle mass was measured using dual-energy X-ray absorptiometry and normalised to the square of height (ASM/ht2). Muscle strength was assessed using the hand grip strength (HGS) test. The definitions of low muscle mass (LMM) and low muscle strength (LMS) were based on the Asian Working Group for Sarcopenia.

RESULTS

plasma FGF21 was significantly lower in participants with LMM than in those with normal muscle mass (289.7 [192.4-448.3] vs. 345.6 [238.6-503.2] pg/ml, P = 0.008). In contrast, the LMS group had a significantly higher plasma FGF21 level than the normal muscle strength group (369.7 [244.4-591.1] vs. 309.7 [205.3-444.8] pg/ml, P = 0.006). In the partial correlation analysis, following adjustment for age, sex and body mass index, FGF21 levels had no significant association with ASM/ht2, but were negatively associated with HGS (r = -0.112, P = 0.029). Furthermore, after multivariate adjustment for confounding variables, the odds ratio for the risk of LMS was 2.32 (95% confidence interval 1.20-4.46) when comparing the highest with the lowest FGF21 quartile.

CONCLUSIONS

circulating FGF21 levels are negatively associated with muscle strength but are not independently correlated with muscle mass.

摘要

背景

尽管成纤维细胞生长因子 (FGF) 21 在多种代谢疾病中有有益作用，但血浆 FGF21 与肌肉量和肌肉力量的关系仍不清楚。

方法

共分析了 386 名年龄在 70-84 岁的社区居住的老年人。使用双能 X 射线吸收法测量四肢骨骼肌量，并将其归一化为身高的平方 (ASM/ht2)。肌肉力量使用握力 (HGS) 测试进行评估。低肌肉量 (LMM) 和低肌肉力量 (LMS) 的定义基于亚洲肌肉减少症工作组。

结果

与肌肉量正常的参与者相比，LMM 患者的血浆 FGF21 明显较低（289.7 [192.4-448.3] vs. 345.6 [238.6-503.2] pg/ml，P = 0.008）。相反，LMS 组的血浆 FGF21 水平明显高于肌肉力量正常组（369.7 [244.4-591.1] vs. 309.7 [205.3-444.8] pg/ml，P = 0.006）。在偏相关分析中，在校正年龄、性别和体重指数后，FGF21 水平与 ASM/ht2 无显著相关性，但与 HGS 呈负相关（r = -0.112，P = 0.029）。此外，在校正混杂变量后，与最低四分位数相比，最高四分位数的 LMS 风险比为 2.32（95%置信区间 1.20-4.46）。